MicroRNA therapeutics in cardiovascular medicine.
Bottom Line: Cardiovascular diseases are the most common causes of human morbidity and mortality despite significant therapeutic improvements by surgical, interventional and pharmacological approaches in the last decade.An array of animal and even human miRNA-based therapeutic studies has been performed, which validate miRNAs as being successfully targetable to treat a wide range of diseases.Here, the current knowledge about miRNAs therapeutics in cardiovascular diseases on their way to clinical use are reviewed and discussed.
Affiliation: Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany. email@example.comShow MeSH
Related in: MedlinePlus
Mentions: This highlights the need for further understanding of underlying mechanisms and development of innovative effective therapies for heart diseases. A variety of cardiovascular diseases, such as coronary artery disease, hypertension, myocardial infarction, valvular heart diseases, myocarditis and genetic forms of cardiomyopathies often result in a phenotypically similar endpoint, which is heart failure (Hill & Olson, 2008). Exposure of the heart to different stressors leads to cardiac remodelling with finally detrimental outcomes (Fig 1). At the cellular level, there is fibroblast activation and proliferation with subsequently increased growth factor secretion and extracellular matrix (ECM) production leading to fibrosis and further decline in cardiac function (Hill & Olson, 2008). Impaired vascularization and low capillary density as well as inflammatory processes further contribute to the development of heart failure (Fiedler et al, 2011; Heymans et al, 2009). Indeed, alterations of non-cardiomyocytes such as cardiac fibroblasts and endothelial cells strongly impact on cardiomyocyte and thus on general cardiac function.
Affiliation: Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany. firstname.lastname@example.org